Treace Medical Concepts (TMCI) to Release Earnings on Friday

Key Points

• Treace Medical Concepts will report Q1 2026 results before the market opens on Friday, May 8, with analysts expecting EPS of ($0.31) and $45.96 million in revenue and a conference call at 8:00 AM ET.
• The company remains unprofitable — it posted ($0.15) EPS in the last quarter with revenue of $62.52 million, a negative return on equity of 59.91% and a net margin of -27.74%, and analysts forecast roughly -$1 EPS for the current and next fiscal year.
• Shares trade around $1.81 with a market cap of $117.25 million (50‑day SMA $1.62, 200‑day SMA $2.79); analyst consensus is an average rating of "Reduce" with a $4.77 target, and institutional investors own about 84% of the stock.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) is expected to release its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect Treace Medical Concepts to post earnings of ($0.31) per share and revenue of $45.96 million for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 8, 2026 at 8:00 AM ET.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last announced its quarterly earnings results on Friday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). Treace Medical Concepts had a negative return on equity of 59.91% and a negative net margin of 27.74%.The business had revenue of $62.52 million during the quarter, compared to the consensus estimate of $61.76 million. On average, analysts expect Treace Medical Concepts to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Treace Medical Concepts Price Performance

Shares of NASDAQ:TMCI opened at $1.81 on Friday. The company has a current ratio of 4.31, a quick ratio of 3.13 and a debt-to-equity ratio of 0.64. The stock has a market cap of $117.25 million, a PE ratio of -1.93 and a beta of 0.87. The stock's fifty day simple moving average is $1.62 and its two-hundred day simple moving average is $2.79. Treace Medical Concepts has a 1-year low of $1.17 and a 1-year high of $7.78.

Institutional Investors Weigh In On Treace Medical Concepts

Several large investors have recently made changes to their positions in the business. Hsbc Holdings PLC purchased a new position in shares of Treace Medical Concepts in the 4th quarter worth about $60,000. XTX Topco Ltd purchased a new stake in Treace Medical Concepts during the fourth quarter worth about $180,000. Quadrature Capital Ltd bought a new stake in Treace Medical Concepts in the fourth quarter worth about $149,000. Moore Capital Management LP raised its position in Treace Medical Concepts by 50.5% in the fourth quarter. Moore Capital Management LP now owns 222,110 shares of the company's stock worth $544,000 after acquiring an additional 74,503 shares during the period. Finally, Engineers Gate Manager LP purchased a new position in Treace Medical Concepts in the fourth quarter valued at about $109,000. 84.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on TMCI shares. Wall Street Zen upgraded shares of Treace Medical Concepts from a "strong sell" rating to a "sell" rating in a report on Monday. Stifel Nicolaus cut their price target on shares of Treace Medical Concepts from $5.00 to $3.00 and set a "hold" rating on the stock in a report on Wednesday, January 7th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Treace Medical Concepts in a research report on Monday, April 20th. Finally, Lake Street Capital decreased their price objective on shares of Treace Medical Concepts from $7.50 to $7.00 and set a "buy" rating for the company in a research note on Monday, March 2nd. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Treace Medical Concepts has an average rating of "Reduce" and an average target price of $4.77.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company's flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.